Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPX4 | P36969 | 1/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.57 |
| ▸ | HRH1 | P35367 | 5/20 | 0.55 |
| ▸ | DRD3 | P35462 | 5/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.55 |
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | HTR2B | P41595 | 3/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.55 |
| ▸ | HRH2 | P25021 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | TEK | Q02763 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.54 |
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.54 |
| ▸ | CACNB1 | Q02641 | 4/20 | 0.54 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.54 |
| ▸ | DRD2 | P14416 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1138094 | 1.00 | GPX4 (0.61) | GPX4OPRD1HRH1DRD3KCNH2 | |
| SCHEMBL1137999 | 0.84 | MEN1 (0.56) | GPX4OPRD1HRH1DRD3KCNH2 | |
| SCHEMBL1137996 | 0.84 | MEN1 (0.56) | GPX4OPRD1HRH1DRD3KCNH2 | |
| SCHEMBL1138154 | 0.82 | HRH1 (0.56) | OPRD1HRH1DRD3KCNH2HTR2A | |
| SCHEMBL1138150 | 0.82 | HRH1 (0.56) | OPRD1HRH1DRD3KCNH2HTR2A | |
| Hydrochloric Acid SCHEMBL1138329 | 0.81 | HRH1 (0.57) | OPRD1HRH1DRD3KCNH2HTR2A | |
| SCHEMBL27673545 | 0.81 | KCNH2 (0.61) | OPRD1HRH1DRD3KCNH2HTR2A | |
| SCHEMBL27624987 | 0.81 | KCNH2 (0.61) | OPRD1HRH1DRD3KCNH2HTR2A | |
| SCHEMBL6554453 | 0.81 | KCNH2 (0.61) | OPRD1HRH1DRD3KCNH2HTR2A | |
| SCHEMBL1138175 | 0.80 | DRD3 (0.59) | OPRD1HRH1DRD3KCNH2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487810-B9 | 4-(DIARYLMETHYL)-1-PIPERAZINYL DERIVATIVES | SUN PHARMA ADVANCED RES CO LTD (IN) | 2011-02-23 | — | — | EP | disclosed |
| EP-1487810-B1 | 4-(DIARYLMETHYL)-1-PIPERAZINYL DERIVATIVES | SUN PHARMA ADVANCED RES CO LTD (IN) | 2010-02-17 | — | — | EP | disclosed |
| US-7297697-B2 | with alkenyl moiety substituted at the 1-position of the piperazine unit; useful in the treatment of histamine mediated diseases | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2007-11-20 | — | — | US | disclosed |
| US-20050107393-A1 | 4-(diarylmethyl)-1-piperazinyl derivatives | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2005-05-19 | — | — | US | disclosed |
| EP-1487810-A2 | 4-(DIARYLMETHYL)-1-PIPERAZINYL DERIVATIVES | Sun Pharmaceuticals Industries Ltd. (IN) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003079970-A2 | 4-(DIARYLMETHYL)-1-PIPERAZINYL DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107393-A1 | 4-(diarylmethyl)-1-piperazinyl derivatives | NPY2R, NPY1R, CBR3 | GPX4 3064/4885OPRD1 24/4885HRH1 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.